DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

2076
INDEX
Tenecteplase, 866
Teniposide, 1668t–1670t, 1716
polymorphisms and response to,
159t
Tenofovir, 106t
absorption of, 1637
antiviral activity of, 1637
chemistry of, 1637
distribution of, 1637
drug interactions with, 1637–1638
elimination of, 1637
for hepatitis, 1617
mechanism of action, 1637
pharmacokinetics of, 1892t
precautions with, 1637–1638
resistance to, 1637
therapeutic use of, 1638
untoward effects of, 1637
Tenon’s capsule, 1773
TEPP. See Tetraethyl pyrophosphate
(TEPP)
Teratogenicity, 1846
of niacin, 901
Terazosin, 306f, 307
adrenergic receptors and, 206t
as antihypertensive agent, 774t,
779–780
pharmacokinetics of, 1892t
Terbinafine, 1586, 1588
for cutaneous fungal infection, 1818
indications for, 1816t
for onychomycosis, 1818
for tinea capitis, in children, 1818
Terbutaline, 293
adrenergic receptors and, 206t
polymorphisms and response to,
160t
selective β 2
, 1848
Terconazole, 1587
for vaginal candidiasis, 1842t
Terfenadine, 920, 924
drug interactions with, 130
polymorphisms and response to,
159t
Teriparatide, 1300
Terminal reticulum, 176
Terminology, phenotype-driven,
146–147
Testicular cancer, drugs for,
1668t–1670t
Testing
animal, 78
genetic, 151–152
safety, 78–79, 142
Testosterone
in aging, 1199
Testosterone (Cont.):
deficiency, 1199–1200
for female hypogonadism, 1203
in infancy, 1198
metabolism to active and inactive
compounds, 1195–1197
pharmacological effects of,
1197–1199
physiological effects of, 1197–1199
puberty and, 1198
secretion and transport of, 1195
secretion inhibitors, 1204–1205
therapeutic preparations, 1200
in utero effects of, 1198
Testosterone, ABC transporters and,
105t
Testosterone esters, 1200
Testosterone propionate, 1668t–1670t
Tetracaine, 574
Tetracycline(s), 1520–1526
for acne, 1817
adverse effects and side effects of,
1817
bone tissue binding and, 24
hypoglycemia and, 1248t
for malaria, 1394t, 1410–1411
ocular effects of, 1793
Tetraethyl pyrophosphate (TEPP), 239
Tetrahydrocannabinol (THC), 941
Tetrodotoxin, 182–183, 575
TEVETEN (eprosartan), 738
TFPI. See Tissue factor pathway
inhibitor (TFPI)
TGF-β. See Transforming growth
factor β (TGF-β)
Thalidomide, 1021–1022
adverse effects and side effects of,
1742, 1824
anti-angiogenic activity, 1740
antimyeloma activity, mechanism of
action of, 1741, 1741f
in cancer treatment, 1740–1742
in dermatology, 1824
drug interactions with, 1742
history of, 7
mechanism of action of,
1820t, 1824
pharmacokinetics of, 1741–1742,
1892t
pharmacology of, 1742
for pruritus, 1828t
structure of, 1741
teratogenicity of, 1741, 1824, 1846
therapeutic uses of, 1741–1742
THALOMID (thalidomide), 1741–1742,
1824
Theophylline
arrhythmias caused by, 821t, 832
hypoglycemia and, 1248t
metabolism of, 128t
Therapeutic action interaction,
77–78
Therapeutic drug monitoring, 37–38
Therapeutic toxicity, 79–80
Thiamine-responsive megaloblastic
anemia (TRMA), 102t
Thiazide diuretics, 686–690
as antihypertensive agents, 774t,
775–777
excretory and renal hemodynamic
effects of, 678t, 687–689
mechanism of action of, 684f, 687
for osteoporosis, 1300
pharmacology of, 688t
precautions with, 777
and renal hemodynamics, 689
structure of, 688t
therapeutic uses of, 689–690
for heart failure, 791
Thiazide diuretics, SLC transporters
and, 102t
Thiazolidinediones, 1260–1262
effects on ovulation and fertility,
1845
Thienopyridines, antiplatelet effects,
849
Thiethylperazine, as antinausea agent,
in cancer chemotherapy,
1344t
Thioguanine, 1668t–1670t
mercaptopurine and, 158
metabolism of, 139
6-thioguanine nucleotides, 139
Thiol methyltransferase (TMT),
138
Thiopental
dosing of, 538t
fat binding with, 24
formulations of, 538t
pharmacology of, 538t, 544t
redistribution of, 25
structure of, 471t
Thioperamide, 925
6-Thiopurine analogs, 1701–1702
Thiopurine derivatives, 1357–1358
Thiopurine methyltransferase (TPMT),
139
and azathioprine therapy, 1821
drug metabolism and, 138
phenotypic traits in metabolism of,
146
polymorphisms and, 158, 159t